Protagonist Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for PTG-300, the company’s sub-cutaneous injectable hepcidin mimetic for the treatment of beta-thalassemia.   “Beta-thalassemia is a rare genetic blood disorder that is characterized by impaired red blood cell production that can result in life-threatening chronic anemia, usually requiring regular and life-long blood transfusions for survival. Over time, the...